Global Central Precocious Puberty Cpp Treatment Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2022 –2029 |
 Tamanho do mercado (ano base ) | USD 1,482.52 Million |
 Tamanho do mercado ( Ano de previsão) | USD 2,663.78 Million |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado global de tratamento da puberdade precoce central (CPP) , por tipo (medicamento, cirurgia ), diagnóstico (exames ao sangue, ressonância magnética, tomografia computorizada, raios X), mês (1 mês, 2 meses, 6 meses, outros), Via de Administração (Parenteral, Implantes, Oral, Outros), Género (Raparigas, Rapazes), Utentes Finais (Hospitais, Clínicas Especializadas, Homecare, Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online, Outros) – Indústria Tendências e previsões para 2029.
Análise e dimensão do mercado
Nos últimos anos, prevê-se que o mercado central de tratamento da puberdade precoce (CPP) cresça rapidamente durante o período de previsão. Os agonistas da hormona libertadora de gonadotrofinas (GnRH) podem ser utilizados para tratar a PPC porque bloqueiam os efeitos estimulantes do GnRH endógeno e aceleram o desenvolvimento ósseo, prevenindo a puberdade precoce. A menarca é atrasada quando o tratamento com GnRH é utilizado para atrasar o início da puberdade. Triptodor, Lupron Depot-Ped (acetato de leuprolida) e Supprelin LA (acetato de histrelina) são três medicamentos terapêuticos aprovados para a puberdade precoce central atualmente no mercado (CPP).
A Data Bridge Market Research analisa que o mercado central de tratamento da puberdade precoce (CPP) foi avaliado em 1.482,52 milhões de dólares em 2021 e deverá atingir os 2.663,78 milhões de dólares até 2029, registando um CAGR de 7,60% durante o período de previsão de 2022 a 2029. O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui análise especializada aprofundada, epidemiologia do paciente, análise de pipeline, análise de preços e estrutura regulamentar.
Definição de mercado
A puberdade precoce dependente de gonadotrofinas é referida como puberdade precoce central (PPC). É uma perturbação do desenvolvimento endócrino marcada pelo início de alterações puberais, características sexuais secundárias, crescimento mais rápido e maturação óssea antes da idade típica da puberdade (8 anos nas raparigas e 9 anos nos rapazes). Este é um distúrbio idiopático. No entanto, as mutações no gene MKRN3 são a causa genética conhecida mais comum de puberdade precoce central.
Âmbito do relatório e segmentação de mercado
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (personalizável para 2019 - 2014) |
|
Unidades Quantitativas |
Receita em milhões de dólares, volumes em unidades, preços em dólares |
|
Segmentos cobertos |
Tipo (medicamento, cirurgia), diagnóstico (análises ao sangue, ressonância magnética, TAC, raios X), mês (1 mês, 2 meses, 6 meses, outros), via de administração (parenteral, implantes, oral, outros)) , Género (raparigas, rapazes), utilizadores finais (hospitais, clínicas especializadas, cuidados domiciliários, outros), canal de distribuição (farmácia hospitalar, farmácia de retalho, farmácia online, outros) |
|
Países abrangidos |
EUA, Canadá e México na América do Norte, Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa, China, Japão, Índia, Coreia do Sul, Singapura, Malásia , Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC) na Ásia-Pacífico (APAC), Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Israel, Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA), Brasil, Argentina e Resto da América do Sul como parte da América do Sul |
|
Participantes do mercado abrangidos |
Sanofi (França), Pfizer Inc. (EUA), GlaxoSmithKline plc (Reino Unido), Novartis AG (Suíça), AbbVie Inc. Pharmaceutical Industries Ltd.(Irlanda), Ipsen Pharma (França), Arbor Pharmaceuticals (EUA), Tolmar Pharmaceuticals , Inc. (EUA), GP Pharm (Espanha), Debiopharm (Suíça), DAEWOONG PHARMACEUTICAL CO., LTD (Coreia do Sul) (Índia), Takeda Pharmaceutical Company Limited (Japão), Endo International plc (Irlanda), AstraZeneca ( Reino Unido), Johnson & Johnson Private Limited (EUA) |
|
Oportunidades de mercado |
|
Dinâmica de mercado do tratamento da puberdade precoce central (CPP)
Motoristas
- Aumento da prevalência de distúrbios hormonais
Estima-se que a crescente prevalência de distúrbios hormonais influencie a taxa de crescimento do mercado. Juntamente com isto, as crescentes incidências de obesidade influenciarão a dinâmica do mercado durante o período de previsão.
- Aumentar o investimento em infraestruturas de saúde
Outro factor significativo que influencia a taxa de crescimento do mercado central de tratamento da puberdade precoce (PPC) é o aumento dos gastos em saúde que ajuda a melhorar as suas infra-estruturas.
Além disso, as crescentes iniciativas de organizações públicas e privadas para difundir a consciência irão expandir o mercado central de tratamento da puberdade precoce (PPC). Além disso, o elevado rendimento disponível e o aumento da procura de tratamentos específicos para as doenças resultarão na expansão do mercado central de tratamento da puberdade precoce (PPC). Juntamente com isto, o aumento do uso de radiação ou quimioterapia para o tratamento do cancro e do estilo de vida sedentário das pessoas aumentará a taxa de crescimento do mercado.
Oportunidades
- Aumento do número de atividades de investigação e desenvolvimento
Além disso, o crescimento do mercado é alimentado por um aumento do número de atividades de investigação e desenvolvimento. Isto proporcionará oportunidades benéficas para o crescimento no mercado central de tratamento da puberdade precoce (PPC). Juntamente com isto, o aumento das aprovações e lançamentos de medicamentos impulsionará ainda mais a taxa de crescimento do mercado.
Além disso, o aumento do investimento para o desenvolvimento de tecnologias avançadas e o aumento do número de mercados emergentes proporcionarão ainda mais oportunidades benéficas para o crescimento do mercado central de tratamento da puberdade precoce (CPP) durante o período de previsão.
Restrições/Desafios
Por outro lado, o elevado custo associado ao tratamento irá obstruir o ritmo de crescimento do mercado. A escassez de profissionais qualificados e a falta de infra-estruturas de saúde nas economias em desenvolvimento desafiarão o mercado central de tratamento da puberdade precoce (PPC). Além disso, um declínio nas visitas clínicas devido ao surto de COVID-19 e à falta de sensibilização entre as pessoas atuará como restrição e impedirá ainda mais a taxa de crescimento do mercado durante o período de previsão de 2022-2029.
Este relatório central do mercado de tratamento da puberdade precoce (CPP) fornece detalhes dos novos desenvolvimentos recentes, regulamentos comerciais, análise de importação-exportação, análise de produção, otimização da cadeia de valor, quota de mercado, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsos emergentes receitas, alterações nas regulamentações do mercado, análise estratégica do crescimento do mercado, tamanho do mercado, crescimento do mercado da categoria, nichos de aplicação e domínio, aprovações de produtos, lançamentos de produtos, expansões geográficas , inovações tecnológicas no mercado. Para mais informações sobre o mercado de tratamento da puberdade precoce central (CPP), contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a tomar uma decisão de mercado informada para alcançar o crescimento do mercado .
Análise Epidemiológica do Doente
Uma em cada 5.000 a 10.000 raparigas sofre de puberdade precoce central. Embora a prevalência da doença não seja clara nos rapazes, é menos prevalente nos rapazes.
O mercado central de tratamento da puberdade precoce (CPP) também fornece análises de mercado detalhadas para análise de pacientes, prognóstico e curas. Prevalência, incidência, mortalidade, taxas de adesão são algumas das variáveis de dados disponíveis no relatório. As análises de impacto direto ou indireto da epidemiologia no crescimento do mercado são analisadas para criar um modelo estatístico multivariado mais robusto e de coorte para prever o mercado no período de crescimento.
Impacto do COVID-19 no mercado de tratamento da puberdade precoce central (CPP)
The COVID-19 outbreak and subsequent lockdown in different nations had an impact on enterprises in all areas, including private healthcare. Due to heavy lockdown in certain places, the COVID-19 pandemic had disrupted the whole healthcare supply chain. The COVID-19 outbreak has had a three-fold influence on the economy of different countries worldwide: directly influencing production and demand, disrupting distribution routes, and having a financial impact on corporations and financial markets. Due to a decline in the supply of raw materials and pharmaceutical medications by manufacturing businesses linked with central precocious puberty, the impact of the COVID-19 pandemic is likely to hinder the growth of the global central precocious puberty market during the forecast period.
Global Central Precocious Puberty (CPP) Treatment Market Scope
The central precocious puberty (CPP) treatment market is segmented on the basis of type, month, route of administration, gender, diagnosis, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Medication
Long-acting Analogs of Gnrh (Gonadotrophin-Releasing Hormones)
- Leuprolide Acetate
- Triptoreline
- Histrelin Acetate
- Others
Adjunctive Treatments
- Surgery
Diagnosis
- Blood tests
- MRI
- CT scans
- X-rays
Month
- 1-Month
- 2-Month
- 6-Month
- Others
Route of Administration
- Parenteral
Subcutaneous
Intramuscular
Others
- Implants
- Oral
- Others
Gender
- Girls
- Boys
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Central Precocious Puberty (CPP) Treatment Market Regional Analysis/Insights
The Central precocious puberty (CPP) treatment market is analysed and market size insights and trends are provided by country, type, month, route of administration, gender, diagnosis, end-users and distribution channel as referenced above.
The countries covered in the Central precocious puberty (CPP) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
A América do Norte domina o mercado central de tratamento da puberdade precoce (PPC) devido à infraestrutura de saúde bem estabelecida nesta região. Além disso, o crescente foco dos principais intervenientes nas novas tecnologias impulsionará ainda mais a taxa de crescimento do mercado nesta região.
Espera-se que a Ásia-Pacífico cresça durante o período de previsão de 2022 a 2029 devido à crescente incidência de obesidade e ao aumento dos gastos com a saúde nesta região.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Análise do cenário competitivo e da quota de mercado do tratamento da puberdade precoce central (CPP)
O cenário competitivo do mercado de tratamento da puberdade precoce central (CPP) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de tratamento da puberdade precoce central (PPC).
Alguns dos principais players que operam no mercado do tratamento da puberdade precoce central (CPP) são:
- Sanofi (França)
- (EUA)
- GlaxoSmithKline plc (Reino Unido)
- Novartis AG (Suíça)
- (EUA)
- F. Hoffmann-La Roche Ltd. (Suíça)
- Mylan NV (EUA)
- Teva Pharmaceutical Industries Ltd.(Irlanda)
- Ipsen Pharma (França)
- Arbor Pharmaceuticals (EUA)
- (EUA)
- GP Pharm (Espanha)
- Debiopharm (Suíça)
- DAEWOONG PHARMACEUTICAL CO., LTD (Coreia do Sul)
- Sun Pharmaceutical Industries Ltd. (Índia)
- Takeda Pharmaceutical Company Limited (Japão)
- Endo International plc (Irlanda)
- AstraZeneca (Reino Unido)
- Johnson & Johnson Private Limited (EUA)
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MARKET MONTH COVERAGE GRID
2.8 TYPE OF CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT LIFELINE CURVE
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 EPIDEMIOLOGY
6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: REGULATIONS
7 ASSUMPTIONS
7.1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE
7.2 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH
7.3 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER
7.5 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER
7.6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING PREVALENCE OF HORMONAL DISORDERS
8.1.2 INCREASING PREVALENCE OF OBESITY
8.1.3 INCREASING CASES OF GRANULOSA CELL TUMOURS
8.1.4 INCREASING GLOBAL HEALTHCARE EXPENDITURE
8.1.5 FAVOURABLE GOVERNMENT SUPPORT FOR PRODUCT APPROVAL
8.2 RESTRAINTS
8.2.1 HIGH TREATMENT COSTS
8.2.2 ADVERSE EFFECTS ASSOCIATED WITH DRUG ADMINISTRATION
8.2.3 COMPLICATIONS ASSOCIATED WITH DIAGNOSIS OF CENTRAL PRECOCIOUS PUBERTY
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
8.3.2 PRESENCE OF STRONG PRODUCT PIPELINE
8.3.3 LAUNCH OF AWARENESS CAMPAIGNS
8.3.4 AVAILABILITY OF OFF LABEL DRUGS
8.4 CHALLENGES
8.4.1 EXISTENCE OF ALTERNATIVE TREATMENT METHODS
8.4.2 INADEQUATE REIMBURSEMENT POLICIES
8.4.3 PATENT EXPIRY
9 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON SUPPLY CHAIN
9.3 IMPACT ON DEMAND
9.4 GOVERNMENT INITIATIVE
9.5 STRATEGIC DECISIONS FOR MANUFACTURERS
9.6 CONCLUSION
10 GLOBAL CENTRAL PRECOCIOUS PUBERTY TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES)
10.2.1.1 LEUPROLIDE ACETATE
10.2.1.2 TRIPTORELIN
10.2.1.3 HISTRELIN ACETATE
10.2.1.4 OTHERS
10.2.2 ADJUNCTIVE TREATMENTS
10.2.2.1 AROMATASE INHIBITORS
10.2.2.2 GROWTH HORMONE
10.2.2.3 NONAROMATIZABLE ANABOLIC STEROIDS
10.3 SURGERY
11 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH
11.1 OVERVIEW
11.2 1- MONTH
11.3 3- MONTH
11.4 6- MONTH
11.5 OTHERS
12 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.2.1 SUBCUTANEOUS
12.2.2 INTRAMUSCULAR
12.2.3 OTHERS
12.3 ORAL
12.4 IMPLANTS
12.5 OTHERS
13 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER
13.1 OVERVIEW
13.2 GIRLS
13.3 BOYS
14 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOMECARE
14.5 OTHERS
15 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACIES
15.4 RETAIL PHARMACIES
15.5 ONLINE PHARMACIES
15.6 OTHERS
16 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GEOGRAPHY
16.1 OVERVIEW
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 FRANCE
16.3.3 U.K
16.3.4 ITALY
16.3.5 NETHERLANDS
16.3.6 SPAIN
16.3.7 RUSSIA
16.3.8 SWITZERLAND
16.3.9 TURKEY
16.3.10 AUSTRIA
16.3.11 NORWAY
16.3.12 HUNGARY
16.3.13 LITHUANIA
16.3.14 IRELAND
16.3.15 POLAND
16.3.16 REST OF EUROPE
16.4 ASIA-PACIFIC
16.4.1 JAPAN
16.4.2 CHINA
16.4.3 AUSTRALIA
16.4.4 SOUTH KOREA
16.4.5 INDIA
16.4.6 SINGAPORE
16.4.7 MALAYSIA
16.4.8 THAILAND
16.4.9 INDONESIA
16.4.10 PHILIPPINES
16.4.11 VIETNAM
16.4.12 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 PERU
16.5.4 REST OF SOUTH AMERICA
16.6 MIDDLE EAST & AFRICA
16.6.1 SAUDI ARABIA
16.6.2 SOUTH AFRICA
16.6.3 UAE
16.6.4 ISRAEL
16.6.5 EGYPT
16.6.6 KUWAIT
16.6.7 REST OF MIDDLE EAST & AFRICA
17 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 COMPANY PROFILES
18.1 ABBVIE INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 ENDO INTERNATIONAL PLC
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 DAEWOONG PHARMACEUTICAL CO.,LTD
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPNAY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 IPSEN PHARMA
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS
18.6 ARBOR PHARMACEUTICALS
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 ASTRAZENECA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 SANOFI
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 DEBIOPHARM
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 GP PHARM
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 MYLAN N.V.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 PFIZER INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 TOLMAR PHARMACEUTICALS, INC.
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS FOR CENTRAL PRECOCIOUS PUBERTY
TABLE 3 MEDICINES SUBJECTED TO PATENT EXPIRY
TABLE 4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE, 2019-2027 (EURO MILLION)
TABLE 5 GLOBAL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 6 GLOBAL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 7 GLOBAL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 8 GLOBAL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 9 GLOBAL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 10 GLOBAL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 11 GLOBAL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 12 GLOBAL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 13 GLOBAL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 14 GLOBAL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 15 GLOBAL SURGERIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 16 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH, 2019-2027 (EURO MILLION)
TABLE 17 GLOBAL 1- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 18 GLOBAL 3- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 19 GLOBAL 6- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 20 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 21 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)
TABLE 22 GLOBAL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 23 GLOBAL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 24 GLOBAL ORAL IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 25 GLOBAL IMPLANT IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 26 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 27 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER, 2019-2027 (EURO MILLION)
TABLE 28 GLOBAL GIRLS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 29 GLOBAL BOYS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 30 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER, 2019-2027 (EURO MILLION)
TABLE 31 GLOBAL HOSPITALS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 32 GLOBAL SPECILATY CLINICS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 33 GLOBAL HOME CARE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 34 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 35 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)
TABLE 36 GLOBAL DIRECT TENDER IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 37 GLOBAL HOSPITAL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 38 GLOBAL RETAIL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 39 GLOBAL ONLINE PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)
TABLE 40 GLOBAL OTHERS IN CNETRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)
TABLE 41 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)
TABLE 42 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 43 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 44 NORTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 45 NORTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 46 NORTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 47 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 48 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 49 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 50 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 51 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 52 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 53 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 54 NORTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 55 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 56 NORTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 57 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 58 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 59 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 60 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 61 U.S. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 62 U.S. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 63 U.S. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 64 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 65 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 66 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 67 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 68 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 69 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 70 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 71 U.S. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 72 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 73 U.S. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 74 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 75 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 76 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 77 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 78 CANADA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 79 CANADA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 80 CANADA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 81 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 82 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 83 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 84 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 85 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 86 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 87 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 88 CANADA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 89 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 90 CANADA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 91 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 92 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 93 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 94 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 95 MEXICO MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 96 MEXICO LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 97 MEXICO ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 98 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 99 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 100 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 101 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 102 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 103 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 104 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 105 MEXICO OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 106 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 107 MEXICO PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 108 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 109 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 110 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 111 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 112 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 113 EUROPE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 114 EUROPE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 115 EUROPE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 116 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 117 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 118 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 119 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 120 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 121 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 122 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 123 EUROPE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 124 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 125 EUROPE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 126 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 127 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 128 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 129 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 130 GERMANY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 131 GERMANY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 132 GERMANY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 133 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 134 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 135 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 136 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 137 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 138 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 139 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 140 GERMANY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 141 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 142 GERMANY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 143 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 144 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 145 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 146 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 147 FRANCE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 148 FRANCE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 149 FRANCE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 150 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 151 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 152 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 153 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 154 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 155 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 156 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 157 FRANCE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 158 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 159 FRANCE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 160 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 161 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 162 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 163 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 164 U.K. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 165 U.K. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 166 U.K. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 167 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 168 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 169 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 170 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 171 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 172 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 173 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 174 U.K. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 175 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 176 U.K. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 177 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 178 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 179 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 180 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 181 ITALY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 182 ITALY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 183 ITALY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 184 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 185 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 186 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 187 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 188 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 189 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 190 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 191 ITALY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 192 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 193 ITALY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 194 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 195 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 196 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 197 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 198 NETHERLANDS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 199 NETHERLANDS LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 200 NETHERLANDS ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 201 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 202 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 203 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 204 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 205 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 206 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 207 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 208 NETHERLANDS OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 209 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 210 NETHERLANDS PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 211 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 212 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 213 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 214 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 215 SPAIN MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 216 SPAIN LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 217 SPAIN ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 218 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 219 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 220 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 221 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 222 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 223 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 224 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 225 SPAIN OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 226 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 227 SPAIN PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 228 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 229 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 230 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 231 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 232 RUSSIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 233 RUSSIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 234 RUSSIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 235 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 236 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 237 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 238 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 239 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 240 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 241 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 242 RUSSIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 243 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 244 RUSSIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 245 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 246 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 247 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 248 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 249 SWITZERLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 250 SWITZERLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 251 SWITZERLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 252 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 253 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 254 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 255 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 256 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 257 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 258 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 259 SWITZERLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 260 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 261 SWITZERLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 262 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 263 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 264 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 265 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 266 TURKEY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 267 TURKEY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 268 TURKEY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 269 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 270 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 271 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 272 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 273 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 274 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 275 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 276 TURKEY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 277 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 278 TURKEY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 279 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 280 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 281 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 282 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 283 AUSTRIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 284 AUSTRIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 285 AUSTRIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 286 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 287 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 288 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 289 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 290 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 291 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 292 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 293 AUSTRIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 294 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 295 AUSTRIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 296 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 297 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 298 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 299 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 300 NORWAY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 301 NORWAY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 302 NORWAY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 303 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 304 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 305 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 306 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 307 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 308 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 309 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 310 NORWAY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 311 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 312 NORWAY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 313 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 314 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 315 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 316 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 317 HUNGARY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 318 HUNGARY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 319 HUNGARY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 320 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 321 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 322 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 323 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 324 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 325 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 326 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 327 HUNGARY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 328 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 329 HUNGARY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 330 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 331 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 332 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 333 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 334 LITHUANIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 335 LITHUANIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 336 LITHUANIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 337 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 338 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 339 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 340 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 341 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 342 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 343 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 344 LITHUANIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 345 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 346 LITHUANIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 347 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 348 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 349 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 350 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 351 IRELAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 352 IRELAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 353 IRELAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 354 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 355 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 356 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 357 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 358 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 359 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 360 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 361 IRELAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 362 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 363 IRELAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 364 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 365 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 366 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 367 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 368 POLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 369 POLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 370 POLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 371 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 372 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 373 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 374 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 375 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 376 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 377 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 378 POLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 379 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 380 POLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 381 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 382 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 383 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 384 REST OF EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 385 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 386 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 387 ASIA-PACIFIC MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 388 ASIA-PACIFIC LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 389 ASIA-PACIFIC ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 390 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 391 ASIA-PACIFIC LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 392 ASIA-PACIFIC LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 393 ASIA-PACIFIC HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 394 ASIA-PACIFIC HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 395 ASIA-PACIFIC TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 396 ASIA-PACIFIC TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 397 ASIA-PACIFIC OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 398 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 399 ASIA-PACIFIC PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 400 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 401 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 402 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 403 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 404 JAPAN MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 405 JAPAN LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 406 JAPAN ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 407 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 408 JAPAN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 409 JAPAN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 410 JAPAN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 411 JAPAN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 412 JAPAN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 413 JAPAN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 414 JAPAN OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 415 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 416 JAPAN PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 417 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 418 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 419 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 420 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 421 CHINA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 422 CHINA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 423 CHINA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 424 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 425 CHINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 426 CHINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 427 CHINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 428 CHINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 429 CHINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 430 CHINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 431 CHINA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 432 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 433 CHINA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 434 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 435 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 436 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 437 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 438 AUSTRALIA. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 439 AUSTRALIA. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 440 AUSTRALIA. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 441 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 442 AUSTRALIA. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 443 AUSTRALIA. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 444 AUSTRALIA. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 445 AUSTRALIA. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 446 AUSTRALIA. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 447 AUSTRALIA. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 448 AUSTRALIA. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 449 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 450 AUSTRALIA. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 451 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 452 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 453 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 454 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 455 SOUTH KOREA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 456 SOUTH KOREA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 457 SOUTH KOREA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 458 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 459 SOUTH KOREA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 460 SOUTH KOREA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 461 SOUTH KOREA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 462 SOUTH KOREA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 463 SOUTH KOREA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 464 SOUTH KOREA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 465 SOUTH KOREA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 466 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 467 SOUTH KOREA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 468 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 469 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 470 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 471 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 472 INDIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 473 INDIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 474 INDIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 475 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 476 INDIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 477 INDIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 478 INDIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 479 INDIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 480 INDIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 481 INDIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 482 INDIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 483 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 484 INDIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 485 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 486 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 487 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 488 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 489 SINGAPORE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 490 SINGAPORE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 491 SINGAPORE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 492 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 493 SINGAPORE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 494 SINGAPORE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 495 SINGAPORE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 496 SINGAPORE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 497 SINGAPORE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 498 SINGAPORE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 499 SINGAPORE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 500 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 501 SINGAPORE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 502 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 503 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 504 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 505 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 506 MALAYSIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 507 MALAYSIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 508 MALAYSIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 509 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 510 MALAYSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 511 MALAYSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 512 MALAYSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 513 MALAYSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 514 MALAYSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 515 MALAYSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 516 MALAYSIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 517 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 518 MALAYSIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 519 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 520 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 521 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 522 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 523 THAILAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 524 THAILAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 525 THAILAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 526 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 527 THAILAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 528 THAILAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 529 THAILAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 530 THAILAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 531 THAILAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 532 THAILAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 533 THAILAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 534 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 535 THAILAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 536 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 537 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 538 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 539 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 540 INDONESIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 541 INDONESIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 542 INDONESIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 543 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 544 INDONESIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 545 INDONESIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 546 INDONESIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 547 INDONESIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 548 INDONESIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 549 INDONESIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 550 INDONESIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 551 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 552 INDONESIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 553 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 554 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 555 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 556 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 557 PHILIPPINES MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 558 PHILIPPINES LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 559 PHILIPPINES ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 560 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 561 PHILIPPINES LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 562 PHILIPPINES LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 563 PHILIPPINES HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 564 PHILIPPINES HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 565 PHILIPPINES TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 566 PHILIPPINES TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 567 PHILIPPINES OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 568 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 569 PHILIPPINES PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 570 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 571 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 572 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 573 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 574 VIETNAM MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 575 VIETNAM LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 576 VIETNAM ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 577 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 578 VIETNAM LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 579 VIETNAM LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 580 VIETNAM HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 581 VIETNAM HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 582 VIETNAM TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 583 VIETNAM TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 584 VIETNAM OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 585 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 586 VIETNAM PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 587 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 588 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 589 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 590 REST OF ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 591 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 592 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 593 SOUTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 594 SOUTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 595 SOUTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 596 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 597 SOUTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 598 SOUTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 599 SOUTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 600 SOUTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 601 SOUTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 602 SOUTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 603 SOUTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 604 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 605 SOUTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 606 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 607 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 608 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 609 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 610 BRAZIL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 611 BRAZIL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 612 BRAZIL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 613 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 614 BRAZIL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 615 BRAZIL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 616 BRAZIL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 617 BRAZIL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 618 BRAZIL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 619 BRAZIL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 620 BRAZIL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 621 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 622 BRAZIL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 623 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 624 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 625 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 626 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 627 ARGENTINA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 628 ARGENTINA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 629 ARGENTINA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 630 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 631 ARGENTINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 632 ARGENTINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 633 ARGENTINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 634 ARGENTINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 635 ARGENTINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 636 ARGENTINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 637 ARGENTINA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 638 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 639 ARGENTINA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 640 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 641 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 642 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 643 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 644 PERU. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 645 PERU. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 646 PERU. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 647 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 648 PERU. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 649 PERU. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 650 PERU. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 651 PERU. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 652 PERU. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 653 PERU. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 654 PERU. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 655 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 656 PERU. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 657 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 658 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 659 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 660 REST OF SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 661 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)
TABLE 662 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 663 MIDDLE EAST & AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 664 MIDDLE EAST & AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 665 MIDDLE EAST & AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 666 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 667 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 668 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 669 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 670 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 671 MIDDLE EAST & AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 672 MIDDLE EAST & AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 673 MIDDLE EAST & AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 674 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 675 MIDDLE EAST & AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 676 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 677 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 678 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 679 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 680 SAUDI ARABIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 681 SAUDI ARABIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 682 SAUDI ARABIAADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 683 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 684 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 685 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 686 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 687 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 688 SAUDI ARABIATRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 689 SAUDI ARABIATRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 690 SAUDI ARABIAOTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 691 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 692 SAUDI ARABIAPARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 693 SAUDI ARABIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 694 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 695 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 696 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 697 SOUTH AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 698 SOUTH AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 699 SOUTH AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 700 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 701 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 702 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 703 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 704 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 705 SOUTH AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 706 SOUTH AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 707 SOUTH AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 708 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 709 SOUTH AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 710 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 711 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 712 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 713 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 714 UAE. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 715 UAE. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 716 UAE. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 717 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 718 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 719 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 720 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 721 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 722 UAE. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 723 UAE. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 724 UAE. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 725 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 726 UAE. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 727 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 728 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 729 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 730 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 731 ISRAEL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 732 ISRAEL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 733 ISRAEL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 734 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 735 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 736 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 737 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 738 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 739 ISRAELTRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 740 ISRAELTRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 741 ISRAEL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 742 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 743 ISRAEL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 744 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 745 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 746 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 747 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 748 EGYPT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 749 EGYPT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 750 EGYPT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 751 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 752 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 753 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 754 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 755 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 756 EGYPT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 757 EGYPT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 758 EGYPT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 759 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 760 EGYPT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 761 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 762 EGYPTCENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 763 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 764 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 765 KUWAIT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 766 KUWAIT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 767 KUWAIT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
TABLE 768 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 769 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 770 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 771 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 772 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 773 KUWAIT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 774 KUWAIT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)
TABLE 775 KUWAIT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)
TABLE 776 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 777 KUWAIT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)
TABLE 778 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)
TABLE 779 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)
TABLE 780 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)
TABLE 781 REST OF MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: MARKET MONTH COVERAGE GRID
FIGURE 8 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 10 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 13 GROWING PREVALENCE OF HORMONAL DISORDERS AND FAVORABLE GOVERNMENT SUPPORT FOR PRODUCT APPROVAL ARE DRIVING THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN 2020 & 2027
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING REGION IN GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET
FIGURE 17 PER CAPITA HEALTHCARE EXPENDITURE, IN 2018 (USD)
FIGURE 18 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, 2019
FIGURE 19 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, 2019-2027 (EURO MILLION)
FIGURE 20 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 21 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, 2019
FIGURE 23 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, 2019-2027 (EURO MILLION)
FIGURE 24 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, CAGR (2020-2027)
FIGURE 25 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, LIFELINE CURVE
FIGURE 26 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 27 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)
FIGURE 28 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 29 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, 2019
FIGURE 31 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, 2019-2027 (EURO MILLION)
FIGURE 32 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, CAGR (2020-2027)
FIGURE 33 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 34 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, 2019
FIGURE 35 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, 2019-2027 (EURO MILLION)
FIGURE 36 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 37 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 39 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)
FIGURE 40 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 41 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 43 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2019)
FIGURE 44 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2020 & 2027)
FIGURE 45 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2019 & 2027)
FIGURE 46 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 47 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 48 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 49 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 50 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 51 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 52 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 53 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 54 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 55 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 56 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 57 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 58 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 59 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 60 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 61 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 62 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 63 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 64 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 65 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 66 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 67 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 68 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 69 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 70 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 71 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 72 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 73 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 74 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 75 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
